A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma



Status:Recruiting
Conditions:Blood Cancer, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:Any
Updated:11/18/2012
Start Date:December 2009
Contact:Elisabeth Sonesson, PhD
Email:elisabeth.sonesson@bioinvent.com
Phone:+46462868550

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Phase I Dose-Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of BI 505, a Human Anti-Intercellular Adhesion Molecule 1 Monoclonal Antibody, in Patients With Relapsed/Refractory Multiple Myeloma


This is a first in human study which will assess the safety and tolerability of a monoclonal
antibody against ICAM-1 in patients with Multiple Myeloma. The tumour response rate will
also be measured.


Inclusion Criteria:

- Advanced Myeloma with measurable disease after at least 2 previous regimens.

- Life expectancy > 3 months.

- Performance status ECOG < 2.

Exclusion Criteria:

- Prior antineoplastic therapy within 4 weeks prior to inclusion.

- No high dose steroids within 7 days prior to screening.

- Severe other conditions.
We found this trial at
2
sites
University of Maryland Greenebaum Cancer Center
22 South Greene Street
Baltimore, Maryland 21201
410-328-7904
University of Maryland Greenebaum Cancer Center The University of Maryland Marlene and Stewart Greenebaum Cancer...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
University of Utah Health Sciences Center, Department of Medicine, Division of Hematology, Utah Blood and Marrow Transplant and Myeloma Program
Salt Lake City, Utah 84132
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials